Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus OMNICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus OMNICEF.
CEFACLOR vs OMNICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours
300 mg orally twice daily for 10 days; or 600 mg orally once daily for 10 days (for community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, uncomplicated skin infections).
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
1.7 hours (range 1.2–2.3 h) in healthy adults; prolonged to 3.2–6.6 h in renal impairment (CrCl <30 mL/min); no significant change in hepatic impairment.
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Renal excretion as unchanged drug: 80-90% (primarily via glomerular filtration and tubular secretion); biliary/fecal: 10-20% (minor).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."